National and Kapodistrian University of Athens
Ρεπερτόριο και λειτουργικότητα υποδοχέων έμφυτης και προσαρμοστικής ανοσίας στη χρόνια λεμφοκυτταρική λευχαιμία
Abstract
dc:descriptionThe role of antigen in the development of CLL is underscored by the biased immunoglobulin (IG) gene repertoire expressed by the malignant clones, the prognostic implications of B-‐cell receptor (BcR) structure and the identification of subsets of patients with quasi-‐identical, stereotyped BcRs. The structural homology of BcRs implies a role for a limited set of antigens or structurally related epitopes in leukemogenesis. Antigen recognition and host defense rely on multiple mechanisms acting synergistically in order to mount an effective immune response. These include specific stimulation through the BcR and non-‐specific stimulation through innate immune receptors, of which the major classes are Toll-‐like receptors (TLRs) and Nod-‐ like Receptors (NLRs). The available data on TLR and NLR expression in CLL are limited and derive from small series of patients. We performed a systematic gene expression profiling of the TLR signaling pathway and NLRs, in a large series of 191 patients with CLL. The analysis extended from all TLRs and NOD1/2 to adaptors, effectors, inhibitors and members of the NFKB, JNK/p38, NF/IL6, and IRF signaling pathways downstream of TLR signaling. In addition, differences in gene expression profiles were sought for among subgroups of cases defined by BcR molecular features, such as the repertoire and mutational status of the IG heavy variable (IGHV) genes or the expression of stereotyped BcRs. CD19+ B lymphocytes were negatively selected from peripheral blood samples. The gene expression profile of the TLR signalling pathway was determined by the RT² Profiler™ PCR Array kit (PAHS-‐ 018A array, SABiosciences), while NOD1/2 expression levels were determined with specific primers. At cohort level, among the receptors, high expression was recorded for TLR7 and CD180, intermediate for TLR1, TLR6 and TLR10 and low expression for TLR2 and TLR9. TLR4 and TLR8 were characterized by low to undetectable expression, with significant variations between patients, while TLR3 and TLR5 were not expressed in any case. The NOD1/2 receptors were highly expressed. The vast majority of adaptors (e.g. MyD88, TICAM1, TRAF6), effectors (UBE2N) and members of the NFKB, JNK/p38, NF/IL6, and IRF signaling pathways downstream of TLR signaling were intermediately-‐to-‐highly expressed, while the inhibitors of TLR activity were generally low-‐to-‐undetectable (TOLLIP, SIGIRR/TIR8). Further comparison in subgroups of cases carrying mutated vs. unmutated IGHV sequences (124 and 67 cases, respectively) revealed upregulation of CD80, CD86, IL6, IFNG and TLR4 and downregulation of TLR8 and NFKBIL1 in the mutated subgroup. Significant differences in gene expression profiles were also found in subgroups of cases with stereotyped receptors. Comparison of subset #4 (mutated IGHV4-‐34/1GKV2-‐30 BcR, 10 cases) vs. subset #1 (unmutated IGHV1/5/7-‐IGKV1(D)-‐39 BcR, 10 cases) vs. subset #8 (unmutated IGHV4-‐39/IGKV1(D)-‐39 BcR, 4 cases) revealed: (i) upregulation of TLR7 and NFKB1A and downregulation of CD86 and TLR4 in #1 vs #4 cases; (ii) upregulation of MAP4K4 and TLR4 and downregulation of NFKB1A and CD180 in #8 vs #1 cases; and, (iii) upregulation of LY96 and downregulation of RIPK2 and CD86 in #8 vs #4 cases. In conclusion, the TLR gene expression profile of CLL is consistent with derivation from antigen-‐experienced B cells. Significant variations were identified in different subgroups of cases defined by BcR molecular features, indicating distinctive activation patterns of the TLR signaling pathway, especially among cases assigned to subsets with stereotyped BcRs. These findings indicate that different or concomitant signals acting through receptors other than the BcR can affect the behavior of the malignant clone. Mature B cells recognize antigens through the B cell receptor (BcR) in a specific way and through innate immunity receptors, such as the Toll-‐like receptors (TLRs) and Nod-‐like receptors (NLRs), in a costimulatory manner. Signaling through the BcR appears to be a major contributing factor in CLL development and, perhaps, evolution. However, the timing, duration and, most importantly, the nature of antigenic exposures remain unclear. Although emerging data suggest that innate immunity receptors are relevant for CLL pathogenesis, the functionality of TLRs and NLRs in CLL is largely unexplored. We investigated TLR and NLR function within CLL subgroups defined by IGHV gene usage, IGHV gene mutational status, or BcR stereotypy. To this end, we studied a series of 67 patients, with an intentional bias to cases expressing stereotyped BcRs assigned to subsets #1 (IGHV1/5/7-‐IGKV1(D)-‐ 39) and #4 (IGHV4-‐34/IGKV2-‐30), which can be considered as prototypes of “unmutated/adverse prognosis” and “mutated/good prognosis” subsets, respectively. Negatively isolated CLL cells were stimulated with specific ligands for all TLRs/NLRs expressed in B cells. The functional outcome was assessed after 24 hours by flow cytometric determination of CD25 and CD86 expression as a measure of cell activation. We also measured cell viability at certain time points. At cohort level, TLR1/2, TLR2/6, TLR9 and NOD2 were responsive to stimulation with their respective ligands in most cases, yet in a heterogeneous fashion. TLR7 stimulation with Imiquimod, a small synthetic antiviral molecule, induced CD25 and/or CD86 in ~50% of cases; in contrast, loxoribine, a naturally occurring TLR7 agonist, had no effects. Markedly different qualitative responses were observed when comparing mutated vs. unmutated CLL cases, with TLR9 upregulating CD86 expression in mutated CLL cases, while TLR7 upregulating CD25 expression in unmutated CLL cases (p<0.05 for all comparisons). Different patterns of functional responses to TLR and NOD2 stimulation were also identified in subsets with stereotyped BcRs. In particular, stimulation of TLR9, TLR1/2, TLR2/6, and NOD2 with the respective ligands strongly upregulated CD86 expression in subset #4 cases, whereas the same treatment had a significantly less pronounced effect on subset #1 cases (p<0.05 for all comparisons). Opposite results were obtained after stimulation of the TLR7 with imiquimod, in that subset #1 cases exhibited stronger up-‐regulation of CD25 expression compared to subset #4 cases (p<0.05). Our study included additional cases belonging to stereotyped subsets #8 (IGHV4-‐39/IGKV1(D)-‐39, unmutated) and #16 (IGHV4-‐ 34/IGKV3-‐20, mutated). Differential, subset-‐biased profiles were also identified when limiting the comparisons to subsets with similar mutational status (i.e. subset #1 vs. #8 and subset #4 vs #16), underscoring the idea of “subset-‐biased” innate immunity responses independently of IGHV gene usage and/or mutational status. To further corroborate this concept, we focused on cases utilizing the IGHV4-‐34 gene, which were intentionally over-‐represented in the cohort. By this approach, we identified significantly (p<0.05) different responses after stimulation of TLR1/2, TLR2/6, TLR9 and NOD2 in subset #4 vs. non subset#4/16 IGHV4-‐34 cases (in terms of induction of either CD25 or CD86 or both. For all the above comparisons, we also identified differential percentages of viable cells after stimulation of certain TLRs and/or NLRs with their respective ligands. In conclusion, we demonstrate that the behavior of CLL malignant B cells can be influenced by signals triggered by innate immunity receptors. CLL patient subgroups defined by specific molecular characteristics of their clonotypic BcRs have distinct patterns of TLR/NLR function and/or TLR tolerance. These differences support the hypothesis that specific modalities of BcR/TLR collaboration and/or regulation may eventually impact on the biological behavior of the malignant clones. Additionally, they might prove relevant both for elucidating the immune mechanisms which underlie CLL development and also for defining subgroups of patients who might benefit from treatment with specific TLR ligands, already used in the clinical setting.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntoufa, Stavroula
- Ντούφα, Σταυρούλα
Subjects
dc:subject × 20- Ανοσία
- Χρόνια λευμφοκυτταρική λευχαιμία
- Ανεργία
- Σηματοδότηση Β λεμφοκυττάρων
- Β κυτταρικός υποδοχέας
- Απόπτωση
- Διέργεση
- Υποδοχείς τύπου Toll
- Toll like receptros (TLRs)
- B cell receptor BCR
- Immunity
- Chronic lymphocytic leukemia
- Apoptosis
- Stimulation
- B cell signaling
- Anergy
- Φυσικές Επιστήμες
- Βιολογία
- Natural Sciences
- Biological Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44120